Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / February / What Cats Can Tell Us About Cancer
Oncology Liquid biopsy Omics Precision medicine Screening and monitoring Research and Innovations Molecular Pathology

What Cats Can Tell Us About Cancer

Large-scale feline sequencing study highlights diagnostic and therapeutic targets shared with human cancers

02/25/2026 News 1 min read

Share

Genetic profiling of nearly 500 domestic cats with cancer has revealed driver mutations that closely mirror those seen in human tumors, positioning feline cancer as a potentially valuable model for diagnostic and therapeutic development.

In the study, published in Science, researchers analyzed 493 tumor–normal tissue pairs spanning 13 feline cancer types. Using targeted sequencing of orthologs of approximately 1,000 human cancer-associated genes, the team identified 31 likely driver genes, viral sequences, mutational signatures, and inherited variants linked to cancer risk.

The most frequently mutated gene across tumor types was TP53, a well-established tumor suppressor in human cancer. Recurrent copy number changes included loss of PTEN or FAS and gain of MYC, alterations that are also common in human malignancies. These parallels suggest that core cancer pathways are conserved across species, supporting the biological relevance of feline tumors for comparative oncology.

Mammary carcinoma, an aggressive and common feline cancer, showed particularly strong overlap with human breast cancer. More than 50 percent of feline mammary tumors harbored alterations in FBXW7, a gene associated with poor prognosis in human breast cancer. The second most common driver in these tumors was PIK3CA, also frequently mutated in human breast cancer and targetable with PI3K inhibitors. In laboratory experiments using cultured tumor tissue, certain chemotherapies appeared more effective in tumors with FBXW7 alterations, highlighting a possible route toward genotype-guided therapy in cats.

Importantly, the project establishes the first large-scale genomic reference dataset for feline cancers. It also opens the possibility that clinical trials in pet cats, who share environmental exposures with their owners, could inform human oncology under the “One Medicine” approach.

Lead researcher, Geoffrey Wood, from the Ontario Veterinary College, Canada, said, “Our household pets share the same spaces as us, meaning that they are also exposed to the same environmental factors that we are. This can help us understand more about why cancer develops in cats and humans, how the world around us influences cancer risk, and possibly find new ways to prevent and treat it.”

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

A Light in the Darkness
Liquid biopsy
A Light in the Darkness

March 4, 2022

2 min read

Spectroscopic liquid biopsy testing – a new route to brain cancer diagnostics

Biomarkers: The Bigger Picture
Liquid biopsy
Biomarkers: The Bigger Picture

April 27, 2022

1 min read

To unlock patient care, pathologists must focus on molecular pathology and ensure efficiency and effectiveness to improve testing. With this testing, patients can benefit from the best treatment to combat their disease.

Benchmarking… Liquid Biopsy
Liquid biopsy
Benchmarking… Liquid Biopsy

May 13, 2022

1 min read

A look at the last five years of publishing on liquid biopsy

Does Your Blood Know You Have Cancer?
Liquid biopsy
Does Your Blood Know You Have Cancer?

July 25, 2022

2 min read

Detection and monitoring are crucial for melanoma outcomes – could a blood test revolutionize both?

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.